Journal article
Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer
CM Cannon, JH Trembley, BT Kren, GM Unger, MG O'Sullivan, I Cornax, JF Modiano, K Ahmed
Human Gene Therapy Clinical Development | MARY ANN LIEBERT, INC | Published : 2017
Abstract
Protein kinase CK2 (CK2) is a highly promising target for cancer therapy, and anti-CK2 gene expression therapy has shown effectiveness in rodent models of human head and neck cancer (HNC). To date, there has been no large-animal model of cancer in which to further explore anti-CK2 therapies. Feline oral squamous cell carcinoma (FOSCC) has been proposed as a large-animal model for human HNC, and we have previously shown that CK2 is a rational target in FOSCC. Here we have tested the hypothesis that a novel tenfibgen-coated tumor-specific nanocapsule carrying RNA interference (RNAi) oligonucleotides targeting feline CK2α and CK2α′ (TBG-RNAi-fCK2αα′) would be safe in cats with FOSCC; assessment..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
The authors thank Rachel Isaakson Vogel for statistical assistance, Paula Overn of the Masonic Cancer Center Comparative Pathology Shared resource for assistance with immunohistochemistry, the Rosol laboratory at Ohio State University for SCCF1 cells and Dr. Frank Ondrey of the University of Minnesota Masonic Cancer Center for UM-SCC-11a cells, and the Clinical Investigations Center at the University of Minnesota College of Veterinary Medicine for assistance with conduction of the clinical trial. The authors acknowledge funding from the National Center for Advancing Translational Sciences of the National Institutes of Health (award number UL1TR000114). This work was also supported by a University of Minnesota Clinical and Translational Sciences Award (1UL1 RR033183-01), by merit review research funds (BX001731 and BX003282) awarded by the Department of Veterans Affairs (K. Ahmed), funds from the Animal Cancer Care and Research Program at the University of Minnesota, and by research grants HHSN26120 1300030C (G.M.U.) and CA150182 (K.A.) awarded by the NCI, NIH, Department of Health and Human Services, and by CA158730 and DK067436-05 awarded by the NCI, NIH, Department of Health and Human Services and the NIDDK, respectively (B.T.K.). The views expressed in this paper are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs or the U.S. government.